期刊文献+

乳腺动态增强MRI时间分辨率对乳腺良、恶性病变药代动力学定量参数及诊断效能的影响 被引量:6

Effect of temporal resolution of breast dynamic contrast-enhancing MRI on pharmacokinetic parameters
原文传递
导出
摘要 目的探讨乳腺动态增强MRI时间分辨率对乳腺良、恶性病变药代动力学定量参数及诊断效能的影响。方法回顾性分析经穿刺活检或手术病理证实的乳腺病变患者,其中良性病灶26个、恶性病灶29个。患者均行动态增强乳腺MRI检查,采用结合并行采集、水脂分离Dixon方法及随机轨迹时间分辨成像技术的容积内插值法屏气检查序列(简称CDT—VIBE序列)。原始序列为时间分辨率12s的动态序列,通过移除采样点的方法分别模拟时间分辨率为24、36、48、60s的动态序列。测量不同时间分辨率乳腺良、恶性病变的定量参数值,包括容量转移常数(Ktrans)、速率常数(Kep)、血管外细胞外间隙容积分数(Ve)和注射对比剂后60s内对比剂浓度.时间曲线下面积(iAUC)。采用重复测量方差分析比较乳腺良、恶性病变不同时间分辨率条件下各定量参数值的差异;以病理结果为金标准,对不同分辨率下各动态参数的诊断效能进行ROE分析,评价各参数的诊断效能。结果随着时间分辨率从12~60S变化,良性病变的K~和K值逐渐升高[Ktrans值为(0.147+0.084)/min~(0.170+0.085)/min,k值为(0.321+0.176)/min~(0.433+0.175)/mini,恶性病变的Ktrans和Kep值逐渐降低[ktrans值为(0.373+0.210)/min~(0.259+0.122)/min,k值为(0.929+0.402)/min~(0.581±0.143)/min];良、恶性病变Ve值的变化幅度较小且无明显规律;良、恶性病变的iAUC值呈下降趋势[良性病变为(9.192+4.660)~(7.388+3.065),恶性病变为(20.221+9.876)-(12.850+5.194)]。不同时间分辨率下,乳腺良、恶性病变的Ktrans、kep、ve和iAUC差异均有统计学意义(P均〈0.05),其中12S、24s与36S间Ktrans值差异有统计学意义(P均〈0.05),12S与其他各时间分辨率间Kep值差异均有统计学意义(P均〈0.01),24S与其他各时间分辨率间Ve值差异均有统计学意义(P均〈0.01),除12S与24S间iAUC值差异无统计学意义外(P=1.000),其余时间分辨率间的iAUC值差异均有统计学意义(P均〈0.05)。Ktrans和Kep在12s动态序列下的曲线下面积最大(分别为0.887、0.939),iAUC在24s动态序列下的曲线下面积最大(0.877),Ve的曲线下面积为0.511~0.601,低于其他参数。结论时间分辨率在24s以上能基本保证药代动力学定量参数计算值相对稳定并具有较好的诊断效能。 Objective To evaluate the effect of temporal resolution of breast dynamic contrast-enhancing (DCE)-MRI on pharmacokinetic parameters and diagnostic performance in benign and malignant breast lesions.Methods Retrospective review was performed on 26 benign and 29 malignant breast lesions which were proven pathologically by surgery or biopsy. Dynamic contrast enhanced breast MRI using a new volume-interpolated-breath-hold examination sequence combining parallel acquisition,Dixon fat separation and time-resolved imaging with interleaved stochastic trajectories (CDT-VIBE) was performed in all patients. The original time resolution of this sequence was 12 s and based on which, dynamic sequences with different temporal resolutions of 24 s, 36 s, 48 s and 60 s were simulated by a sample-removing method and were used for the calculation of pharmacokinetic parameters, including volume transfer constant (Ktrans), constant flux rate (Kep,), volume of extravascular extracellular space (Ve) and area under the curve at initial 60 s (iAUC), to observe their changes with different temporal resolution. The repeated measurement of analysis of variance was used to explore significant changes in pharmacokinetics parameters with different temporal resolution. To evaluate the diagnostic efficiency of parameters with different temporal resolution, ROC analysis was performed in accordance with pathological findings. Results With decrease of temporal resolution from 12 to 60 s, there was a significant increase in Ktrans and Kep, of benign lesions [Ktrans: (0.147 ±0.084)/min to (0.170 ± 0.085)/min, Kep: (0.321 -± 0.176)/min to (0.433± 0.175)/mini and steady decrease in Ktrans and Kep of malignant lesions [Ktrans: (0.373 ±0.210)/rain to (0.259± 0.122)/min, Kep: (0.929± 0.402)/min to (0.581 ± 0.143)/min]; the changes of Vo were less significant and irregular; the values of iAUC decreased both in benign [(9.192 ±4.660) to (7.388± 3.065)] and malignant [(20.221±9.876) to (12.850±5.194)] lesions.The changes in all parameters with different time resolution were statistically significant in benign and malignant lesions (all P〈0.05). By pair-wise comparison between different time resolution, the changes of Ktrans among 12 s, 24 s and 36 s (all P〈0.05), the changes of Kep between 12 s and others (all P〈0.01), the changes of Vo between 24 s and others (all P〈0.01), and the changes among all pairs of iAUC were significant (all P〈0.05) except for 12 s and 24 s (P=1.000). The best AUC value of Ktrans and Kep between benign and malignant lesions were achieved with 12 s dynamic sequences (0.887, 0.939), and the best AUC value of iAUC was with 24 s sequences (0.877). The AUC values of V. were between 0.511 to 0.601, which was lower than that of other three parameters. Conclusion A 24 s or higher temporal resolution of DCE-MRI should be able to provide consistent differentiation of pharmacokinetic parameters in benign and malignant breast lesions.
出处 《中华放射学杂志》 CAS CSCD 北大核心 2015年第11期823-827,共5页 Chinese Journal of Radiology
基金 国家自然科学基金(81371525) 山东省科技发展计划(2008GG30002041)
关键词 乳腺肿瘤 磁共振成像 时间分辨率 Breast neoplasm Magnetic resonance imaging Temporal resolution
  • 相关文献

参考文献16

  • 1Huang W, Tudorica LA, Li X, et al. Discrimination of benign and malignant breast lesions by using shutter-speed dynamic contrast-enhanced MR imaging[J].Radiology, 2011, 261(2): 394-403.
  • 2Schahel MC, Morrell GR, Oh KY, et al. Pharmacokinetic mapping for lesion classification in dynamic breast MR][J].J Magn Reson Imaging, 2010, 31(6):1371-1378.
  • 3Eyal E, Badikhi D, Furman-Haran E, et al. Principal component analysis of breast DCE-MRI adjusted with a model-based method[J].J Magn Reson Imaging, 2009, 30(5): 989-998.
  • 4Planey CR, Welch EB, Xu L, et al. Temporal sampling requirements for reference region modeling of DCE-MRI data in human breast cancer[J].J Magn Reson Imaging, 2009, 30 (1):121-134.
  • 5Aerts HJ, Jaspers K, Backes WH. The precision of pharmacokinetic parameters in dynamic contrast-enhanced magnetic resonance imaging: the effect of sampling frequency and duration[J].Phys Med Biol, 2011, 56(17):5665-5678.
  • 6李瑞敏,顾雅佳,毛健,彭卫军,孙非,谭红娜,唐峰,钱敏.定量动态增强MRI鉴别乳腺良恶性病变的研究[J].中华放射学杂志,2011,45(2):164-169. 被引量:83
  • 7蔡林峰,张梅芳,陈韵彬,陈英,许淑桂.磁共振定量动态增强扫描在乳腺良恶性病变鉴别诊断中的初步应用[J].福建医科大学学报,2013,47(5):313-317. 被引量:3
  • 8Breuer FA, Blaimer M, Mueller MF, et al. Controlled allasmg in volumetric parallel imaging (2D CAIPIRINHA)[J].Magn Reson Med, 2006, 55(3):549-556.
  • 9Breuer FA, Blaimer M, Heidemann RM, et al. Controlled aliasing in parallel imaging results in higher acceleration (CAIPIRINHA) for multi-slice imaging[J].Magn Reson Med, 2005, 53(3):684-691.
  • 10刘亚涛,俎栋林,包尚联.水、脂分离磁共振成像Dixon方法[J].中国医学物理学杂志,2012,29(6):3759-3768. 被引量:16

二级参考文献75

  • 1张嵘,李勇,任俊杰,梁碧玲,文艳玲,李海刚.乳腺叶状瘤的影像诊断[J].中华放射学杂志,2004,38(7):717-720. 被引量:23
  • 2Sinha S,Sinha U.Recent advances in breast MRI and MRS.NMB Biomed,2009,22:3-16.
  • 3Murase K.Efficient method for calculating kinetic parameters using T1-weighted dynamic contrast-enhanced magnetic resonance imaging.Magn Reson Med,2004,51:858-862.
  • 4Yankeelov TE,Lepage M,Chakravarthy A,et al.Integration of quantitative DCE-MRI and ADC mapping to monitor treatment response in human breast cancer:initial results.Magn Reson Imaging,2007,25:1-13.
  • 5Tofts PS,Brix G,Buckley DL,et al.Estimating kinetic parameters from dynamic contrast-enhanced T1 -weighted MRI of a diffusable tracer:standardized quantities and symbols.J Magn Rein Imaging,1999,10:223-232.
  • 6Tavassoli FA,Devillee P.WHO classification of tumours pathology & genetics:tumours of the breast and female genital organs.Lyon:IARC Press,2003:9-112.
  • 7Huang W,Li X,Morris EA,et al.The magnetic resonance shutter speed discriminates vascular properties of malignant and benign breast tumors in vivo.Proc Natl Acad Sci USA,2008,105:17943-17948.
  • 8Barrett T,Brechbiel M,Bernardo M,et aL MRI of tumor angiogenesis.J Magn Reson Imaging,2007,26:235-249.
  • 9Toffs PS.Modeling tracer kinetics in dynamic Gd-DTPA MR imaging J Magn Reson Imaging,1997,7:91-101.
  • 10Wang Y,Huang W,Panicek DM.Feasibility of using limitedpopulation-based arterial input function for pharmacokinetic modeling of osteosarcoma dynamic contrast-enhanced MRI data.Magn Reson Med,2008,59:1183-1189.

共引文献101

同被引文献42

引证文献6

二级引证文献46

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部